Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Zymeworks Inc

(TSX: ZYME.TO)
Add to Portfolio
+0.53 (+1.63%)
as of Oct 1, 2019

Last 33.10
Change +0.53 (+1.63%)
Open 33.05
Prev. Close 32.57
Today's Range
32.77
33.53
52wk Range
14.34
39.10
Volume 5,350
Avg Volume 10,947

Perfomance Comparison

Name Today 3-Month 1-Year
ZYME.TO +1.63% +4.28% +67.94%
$TXCX -0.30% +0.69% +6.32%
$TXSC -0.28% +1.09% +7.48%
DJIA -0.95% +1.49% +5.48%
S&P 500 -0.39% +1.64% +7.85%

Key Statistics

Annual EPS -1.55
Dividend Yield N/A
P/E Ratio N/A
Market Capitalization, $K 1,299,504
Weighted Alpha +91.80
Standard Deviation +0.52
Profit Margin -1.03%
Beta N/A

Growth Rates

YTD +66.16%
1-Year +82.87%

Opinion

Sell Hold Buy

Recent Headlines

Zymeworks Announces Election of Directors and Voting

BusinessWire via COMTEX - Fri May 03, 06:45AM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at(full story)
ZYME: 29.62 (-0.30), ZYME.TO: 33.10 (+0.53)

Zymeworks Reports 2019 First Quarter Financial Results

BusinessWire via COMTEX - Thu May 02, 05:00PM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the first quarter ended March 31, 2019.(full story)
ZYME: 29.62 (-0.30), ZYME.TO: 33.10 (+0.53)

Zymeworks Adds Experienced Executives to Management

BusinessWire via COMTEX - Tue Apr 30, 06:45AM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced it has expanded its leadership team with the hiring of three new vice pre(full story)
ZYME: 29.62 (-0.30), ZYME.TO: 33.10 (+0.53)

Daiichi Sankyo Selects Lead Candidate Built on

BusinessWire via COMTEX - Thu Apr 25, 06:45AM EDT
--Zymeworks to receive US$3.5 million commercial license payment from Daiichi Sankyo(full story)
ZYME: 29.62 (-0.30), ZYME.TO: 33.10 (+0.53)

Zymeworks Opens Phase 2 Clinical Trial for ZW25 in

BusinessWire via COMTEX - Mon Apr 15, 06:45AM EDT
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 (full story)
ZYME: 29.62 (-0.30), ZYME.TO: 33.10 (+0.53)